Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in HER2 amplified metastatic breast cancer (MBC) patients (pts) who had progressed on anti-HER2 ADCs.
暂无分享，去创建一个
F. Cardoso | T. Petit | F. Bidard | M. Mita | B. Pistilli | F. Dalenc | T. Bachelot | A. Gonçalves | V. Dezentjé | S. Graff | E. Hamilton | N. Afonso | V. Stalbovskaya | P. Aftimos | L. Manso | E. Wasserman | A. Vliet | K. Bol | A. Ferreira | S. Escrivá | V. Dezentjé